Allogeneic HPV-specific CD4+ T cells

Allogeneic HPV-specific CD4+ T cells are an experimental adoptive cell therapy developed by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The therapy is designed for patients with advanced HPV16-associated malignancies, such as head and neck squamous cell carcinoma. The production process involves vaccinating a haploidentical relative with a therapeutic HPV16 vaccine to induce a specific immune response. Peripheral blood cells are then harvested from the donor and depleted of CD8+ T cells to minimize the risk of graft-versus-host disease (GvHD) while retaining HPV-specific CD4+ helper T cells. These cells are subsequently infused into the patient to coordinate an anti-tumor immune response against HPV16-positive cells.

Other names

CD8 reduced peripheral blood cellsCD-8 reduced peripheral blood cellsCD 8 reduced peripheral blood cellsCD8-depleted donor lymphocyte infusionCD-8-depleted donor lymphocyte infusionCD 8-depleted donor lymphocyte infusionHPV-specific CD4+ T cellsCD8 reduced peripheral blood cells taken from related donors vaccinated against HPV16CD-8 reduced peripheral blood cells taken from related donors vaccinated against HPV16CD 8 reduced peripheral blood cells taken from related donors vaccinated against HPV16